Dupilumab as a rescue therapy for a chronic urticaria patient who showed secondary failure to omalizumab.
作者信息
Sun Yng, Lin Sheng Yiao, Lan Cheng-Che E
机构信息
Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
出版信息
Kaohsiung J Med Sci. 2022 Jun;38(6):610-611. doi: 10.1002/kjm2.12531. Epub 2022 Apr 8.
Abstract
摘要
相似文献
1
Dupilumab as a rescue therapy for a chronic urticaria patient who showed secondary failure to omalizumab.度普利尤单抗作为对奥马珠单抗继发无效的慢性荨麻疹患者的挽救疗法。
Kaohsiung J Med Sci. 2022 Jun;38(6):610-611. doi: 10.1002/kjm2.12531. Epub 2022 Apr 8.
2
Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.在一名患有慢性自发性荨麻疹和特应性皮炎的47岁女性中同时使用奥马珠单抗和度普利尤单抗。
Int J Dermatol. 2022 May;61(5):e173-e174. doi: 10.1111/ijd.16009. Epub 2021 Nov 23.
3
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.度普利尤单抗治疗慢性自发性荨麻疹患者的疗效和安全性（LIBERTY-CSU CUPID）：两项随机、双盲、安慰剂对照、3 期临床试验。
J Allergy Clin Immunol. 2024 Jul;154(1):184-194. doi: 10.1016/j.jaci.2024.01.028. Epub 2024 Feb 29.
4
Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis.奥马珠单抗和司库奇尤单抗联合治疗一名慢性自发性荨麻疹和银屑病患者。
Dermatol Ther. 2022 Sep;35(9):e15638. doi: 10.1111/dth.15638. Epub 2022 Jul 15.
5
A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.一例对利吉珠单抗无反应的慢性自发性荨麻疹经奥马珠单抗成功治疗的病例。
Dermatol Ther. 2022 Nov;35(11):e15859. doi: 10.1111/dth.15859. Epub 2022 Oct 4.
6
Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review.使用度普利尤单抗治疗难治性慢性荨麻疹：两例对H1抗组胺药、奥马珠单抗和环孢素难治的病例报告及文献简要综述
Dermatol Ther. 2021 Mar;34(2):e14821. doi: 10.1111/dth.14821. Epub 2021 Feb 2.
7
Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience.奥马珠单抗耐药性慢性荨麻疹的患病率及度普利尤单抗在奥马珠单抗难治性慢性荨麻疹患者中的真实世界疗效：单中心经验
Clin Exp Dermatol. 2024 Sep 18;49(10):1227-1231. doi: 10.1093/ced/llae145.
8
Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series.使用替拉珠单抗进行抗白细胞介素-23治疗对奥马珠单抗难治性慢性自发性荨麻疹可能有效：病例系列报道
J Allergy Clin Immunol Pract. 2023 Aug;11(8):2578-2580.e1. doi: 10.1016/j.jaip.2023.05.019. Epub 2023 May 25.
9
Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.利吉珠单抗与奥马珠单抗治疗慢性自发性荨麻疹的疗效比较
Lancet. 2024 Jan 13;403(10422):118-119. doi: 10.1016/S0140-6736(23)02188-8. Epub 2023 Nov 23.
10
Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.慢性自发性荨麻疹和症状性皮肤划痕症患者中奥马珠单抗治疗反应的比较：一项单中心回顾性研究
Int Arch Allergy Immunol. 2023;184(3):236-242. doi: 10.1159/000528048. Epub 2022 Dec 21.
引用本文的文献
1
Dupilumab in Inflammatory Skin Diseases: A Systematic Review.度普利尤单抗治疗炎症性皮肤病：系统评价。
Biomolecules. 2023 Mar 31;13(4):634. doi: 10.3390/biom13040634.
2
Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab.病例报告：奥马珠单抗和度普利尤单抗成功治疗重度慢性自发性荨麻疹
Allergol Select. 2023 Jan 3;7:17-19. doi: 10.5414/ALX02382E. eCollection 2023.
本文引用的文献
1
Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.荨麻疹：国际过敏学会（CIA）2020 年更新。
Int Arch Allergy Immunol. 2020;181(5):321-333. doi: 10.1159/000507218. Epub 2020 Mar 30.
2
Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis.度普利尤单抗在皮肤科的应用：超越特应性皮炎的潜在用途
J Drugs Dermatol. 2019 Oct 1;18(10).
3
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.欧洲过敏研究学会/过敏标准委员会/欧洲皮肤病学会/世界变态反应组织荨麻疹指南：定义、分类、诊断和管理。
Allergy. 2018 Jul;73(7):1393-1414. doi: 10.1111/all.13397.
4
Autoimmune chronic spontaneous urticaria: What we know and what we do not know.自身免疫性慢性自发性荨麻疹：已知与未知。
J Allergy Clin Immunol. 2017 Jun;139(6):1772-1781.e1. doi: 10.1016/j.jaci.2016.08.050. Epub 2016 Oct 21.
5
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.度普利尤单抗可改善中重度特应性皮炎患者的皮肤分子特征。
J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300. doi: 10.1016/j.jaci.2014.10.013.
Zotero 插件